A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 190
- Registration Number
- NCT05155332
- Locations
- 🇦🇹
Salzburg Cancer Research Institute, Salzburg, Austria
🇪🇸Hospital Quiron. I.C.U., Barcelona, Spain
🇺🇸Banner MD Anderson Cancer Center-Gilbert-55251, Gilbert, Arizona, United States
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 160
- Registration Number
- NCT05151640
- Locations
- 🇧🇬
Acibadem CityClinic UMBAL Tokuda Hospital, Sofia, Bulgaria
🇧🇬UMBAL Alexandrovska, Sofia, Bulgaria
🇧🇬MBAL VMA Military Medical Academy, Sofia, Bulgaria
A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 135
- Registration Number
- NCT05151653
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1053
- Registration Number
- NCT05130463
- Locations
- 🇰🇷
Cheonan Chungmu Hospital, Cheonan-si, Chungcheongnam-do, Korea, Republic of
🇰🇷Yeosu Jeil Hospital, Yeosu-si, Jeollanam-do, Korea, Republic of
🇰🇷Gyeongsang National Univ. Changwon Hospital, Changwon-si, Gyeongsangnam-do, Korea, Republic of
A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: Stiolto RespimatDevice: Trelegy ElliptaDrug: Furoate/Umeclidinium/Vilanterol
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11316
- Registration Number
- NCT05127304
- Locations
- 🇺🇸
Optum, Eden Prairie, Minnesota, United States
Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)
- Conditions
- Solid Tumors
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05107193
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 318
- Registration Number
- NCT05103657
- Locations
- 🇺🇸
Behavioral Research Specialists, LLC, Glendale, California, United States
🇺🇸ASCLEPES Research Centers, P.C. dba Alliance Research, Long Beach, California, United States
🇺🇸CalNeuro Research Group Inc., Los Angeles, California, United States
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
- Conditions
- Diabetes Mellitus, Type 2Cardiovascular Diseases
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05102071
- Locations
- 🇺🇸
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
- Conditions
- Gastrointestinal Cancer, Metastatic
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT05087992
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇯🇵National Cancer Center Hospital East, Chiba, Kashiwa, Japan
🇧🇪UZ Leuven, Leuven, Belgium
A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT05083949
- Locations
- 🇧🇷
Instituto de Ciências Farmacêuticas de Estudos e Pesquisas - ICF, Goiânia, Brazil